Related Experiment Video
Updated: Apr 5, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy
Arjun Gupta1, Samar Harris2, Steven Vernino3
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. guptaarjun90@gmail.com.
Abstract:
We present a patient with autoimmune autonomic ganglionopathy (AAG) who had persistently positive ganglionic nicotinic acetylcholine receptor antibody levels despite immunosuppressive therapy. Rituximab-based therapy for an incidental lymphoma was associated with prolonged symptomatic and serological control of AAG.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Rheumatic Heart Disease III: Medical Management
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Drugs Acting on Autonomic Ganglia: Blockers
Cardiomyopathy IV: Restrictive Cardiomyopathy